Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 20/20 | 0.85 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2087442 | 1.00 | CALCRL (0.85) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL2087294 | 0.98 | CALCRL (0.86) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL2087301 | 0.98 | CALCRL (0.86) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL12773023 | 0.96 | CALCRL (0.89) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL2166726 | 0.96 | CALCRL (0.85) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL2166720 | 0.96 | CALCRL (0.85) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL13438326 | 0.95 | CALCRL (0.82) | CALCRLRAMP1 | |
| SCHEMBL12773560 | 0.95 | CALCRL (0.78) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL4142502 | 0.95 | CALCRL (0.82) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL2165277 | 0.95 | CALCRL (0.82) | CALCRLRAMP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176836-A1 | benzodiazepines; 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid-{(R)-1-(4-amino-3-chloro-5-ethyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl}-amide; | RUDOLF KLAUS | 2008-07-24 | — | — | US | claimed |
| US-20080103134-A1 | Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine | RUDOLF KLAUS | 2008-05-01 | — | — | US | claimed |
| US-20060142274-A1 | Use of selected CGRP antagonists for combating menopausal hot flushes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | claimed |
| US-20060142273-A1 | Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | claimed |
| US-7985747-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-26 | — | — | US | disclosed |
| US-7897603-B2 | Selected CGRP-antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| US-20100249114-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100234361-A1 | SELECTED CGRP-ANTAGONISTS, PROCESS FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-7700598-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-20 | — | — | US | disclosed |
| US-7696196-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20090253680-A1 | SELECTED CGRP-ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-7582625-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-7479488-B2 | Selected CGRP—antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-20 | — | — | US | disclosed |
| US-20080176836-A1 | benzodiazepines; 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid-{(R)-1-(4-amino-3-chloro-5-ethyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl}-amide; | RUDOLF KLAUS | 2008-07-24 | — | — | US | disclosed |
| US-20080103134-A1 | Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine | RUDOLF KLAUS | 2008-05-01 | — | — | US | disclosed |
| US-20070072847-A1 | -(4-Hydroxy-3,5-dimethyl-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate; headaches; non-insulin dependent diabetes; antidiabetic agents; cardiovascular/nervous system disorders; antiinflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| US-20060252750-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
| US-20060142274-A1 | Use of selected CGRP antagonists for combating menopausal hot flushes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| US-20060142273-A1 | Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| US-20050234067-A1 | Selected CGRP - antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072847-A1 | -(4-Hydroxy-3,5-dimethyl-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate; headaches; non-insulin dependent diabetes; antidiabetic agents; cardiovascular/nervous system disorders; antiinflammatory agents | GPR119, HTR1D, TRPV1 | CALCRL 9/4885RAMP1 55/4885CYP3A4 664/4885 |
| US-20080176836-A1 | benzodiazepines; 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid-{(R)-1-(4-amino-3-chloro-5-ethyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl}-amide; | GABRA1, GABRA5, GABRA2 | CALCRL 160/4885RAMP1 307/4885CYP3A4 444/4885 |
| US-20090253680-A1 | SELECTED CGRP-ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | CALCRL, CALCR, BDKRB2 | CALCRL 1/4885RAMP1 51/4885CYP3A4 1141/4885 |
| US-20080103134-A1 | Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine | SCN3A, HTR3A, BDKRB2 | CALCRL 39/4885RAMP1 288/4885CYP3A4 3006/4885 |
| US-20050234067-A1 | Selected CGRP - antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 90/4885CYP3A4 1129/4885 |
| US-20060252750-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 92/4885CYP3A4 1182/4885 |
| US-20100249114-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 92/4885CYP3A4 1182/4885 |
| US-20100234361-A1 | SELECTED CGRP-ANTAGONISTS, PROCESS FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 92/4885CYP3A4 1182/4885 |
| US-20060142274-A1 | Use of selected CGRP antagonists for combating menopausal hot flushes | BDKRB2, CALCR, GRPR | CALCRL 4/4885RAMP1 202/4885CYP3A4 2927/4885 |
| US-20060142273-A1 | Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine | SCN3A, HTR3A, BDKRB2 | CALCRL 39/4885RAMP1 288/4885CYP3A4 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.